More to come from Metabulin
A transplant restores density by relocating follicles, but it doesnt treat the underlying trigger of diffuse shedding
The traction device can also be used with medical and surgical therapy as it may enhance the benefits from those other treatment options
What it is: A once-weekly GLP-1 medicine for chronic weight management when combined with diet and activity How it works: Activates GLP-1 receptors in the brain and gut to reduce hunger and increase fullness What to expect: Many patients see steady weight loss over several months as the dose reaches a maintenance level Common considerations: Nausea, mild stomach discomfort, constipation, or diarrhea can occur during dose increases and usually improve with time and meal adjustments What it is: A once-weekly medicine that targets both GIP and GLP-1 receptors How it works: Adds a second pathway that further supports appetite control and metabolic health What to expect: Clinical studies have shown larger average weight reductions at higher doses compared with GLP-1 alone
Transition protocols use roughly 1.6 g/kg/day of protein and progressive resistance training to protect strength as appetite returns
More recently, the approval of the first oral GLP-1 analog, semaglutide (Rybelsus), for type 2 diabetes represents a major step forward in addressing one of the key challenges in this field: patient compliance associated with subcutaneous injections
